Pharmacokinetics of KS-IL-2 with junction alterations (IL-2 ELISA)




Figure 1A

Effect of alteration of fusion junction on pharmacokinetics of KS-IL-2 (Fc ELISA)




Figure 1B

Title: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

Inventor(s): Gillies et al.
Serial No. Not Yet Assigned
Atty Docket No. LEX-011
Atty/Agent: Patrick R. H. Waller
Express Mail Label No. EL280660274US

Pharmacokinetics of KS-IL-2 fusions in wildtype and beta2 mutant mice




Figure 2

Pharmacokinetics of antibody-TNFalpha




Figure 3

fitle: Enhancing the Circulating Hait-Lite of Antibody-Based Fusion Proteins Inventor(s): Gillies et al. Serial No. Not Yet Assigned Atty Docket No. LEX-011

Atty/Agent: Patrick R. H. Waller Express Mail Label No. EL280660274US

Binding of antibody-IL-2 fusion proteins to Fc receptor




Figure 4 (J774 binding)




Figure 5